Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Mebendazole 100mg price?
Is clarinex off patent?
Is allopurinol expensive?
Generic brand for latisse?
Does food increase lipitor's absorption?

Xarelto and bleeding?

See the DrugPatentWatch profile for Xarelto

How does Xarelto (rivaroxaban) affect bleeding risk?

Xarelto is a blood thinner (an anticoagulant). It works by reducing blood clotting, which lowers the risk of stroke or dangerous clots but increases the chance of bleeding. Reported risks include bleeding in places like the gastrointestinal tract (stomach/intestine) and the brain, and bleeding after injury or surgery. [1][2]

What types of bleeding should you watch for while taking Xarelto?

Common signs people report include unusual bruising, nosebleeds, bleeding gums, or bleeding that takes longer than usual to stop. More urgent warning signs include:
- Blood in urine (pink/red urine)
- Black or bloody stools
- Coughing up blood
- Vomiting blood or material that looks like coffee grounds
- Severe headache, sudden weakness, confusion, or trouble speaking (possible serious internal bleeding)
- Heavy or prolonged vaginal bleeding

If any of these occur, especially sudden severe symptoms, seek urgent medical care. [1][2]

When is bleeding risk highest (and who is at greater risk)?

Risk can be higher with factors such as older age, a history of bleeding, kidney impairment, uncontrolled high blood pressure, certain drug combinations (see below), and taking higher-than-prescribed doses. The risk can also rise around surgery, dental procedures, or after trauma. [1][2]

Which medicines increase bleeding risk with Xarelto?

Bleeding risk rises when Xarelto is combined with other medicines that affect clotting or increase anticoagulant levels, including:
- Other anticoagulants or antiplatelet drugs (for example, aspirin or clopidogrel, depending on your regimen)
- Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen
- Some antifungal or antiviral medications that can raise rivaroxaban levels
- Some other CYP3A4/P-gp interacting drugs

Check with your clinician or pharmacist before starting new medications, including over-the-counter pain relievers. [1][2]

What should you do if you start bleeding while on Xarelto?

Minor bleeding (like a small nosebleed) may improve with pressure and local measures, but it’s important to contact your prescriber, especially if it repeats or doesn’t stop promptly. For signs of serious bleeding (black/bloody stools, red/pink urine, vomiting blood, severe headache, weakness/confusion), seek emergency care right away. [1][2]

Do not stop Xarelto on your own without medical advice, because stopping can increase the risk of stroke or clot-related events, depending on why you’re taking it. [1][2]

Does Xarelto have an antidote, and when is it used?

Yes. Xarelto’s anticoagulant effect can be reversed in certain situations using andexanet alfa (for patients with factor Xa inhibitor–associated bleeding) in appropriate clinical settings. For some cases, clinicians may use other reversal approaches depending on availability and patient factors. [1][2]

How does surgery or dental work affect Xarelto bleeding risk?

Bleeding and clot risk are balanced when procedures are planned. Xarelto is often held before surgery or procedures, and the timing depends on kidney function, the dose, and the bleeding risk of the procedure. Your surgeon/dentist and prescribing clinician should coordinate the plan. [1][2]

What if you miss a dose and then bleed?

If you miss a dose, you should follow the dosing instructions provided with your prescription (or your clinician’s guidance). Taking extra doses to “catch up” can raise bleeding risk. If bleeding occurs after a missed dose period, contact your clinician promptly. [1]

Xarelto dose differences: could the dose change bleeding risk?

Yes. Bleeding risk depends partly on dose and indication. Using a dose higher than prescribed increases bleeding risk. Dose selection is also influenced by kidney function and the reason you’re taking Xarelto (for example, atrial fibrillation vs. treatment/prevention of clots). [1][2]

Sources

[Xarelto (rivaroxaban) Prescribing Information – Janssen/EMA] https://www.xarelto.com/
[Xarelto prescribing information (bleeding risk, warnings, reversal)] https://www.ema.europa.eu/

Prescribing Information Alignment Report

Executive Summary

Overall Alignment: Partially Aligned

The AI-generated claims substantially reflect FDA labeling themes that include increased bleeding risk with rivaroxaban, seriousness of bleeding (including intracranial bleeding), and increased thrombotic risk with premature discontinuation. However, several specific counseling details and peri-procedural/interaction statements are not fully supported by the provided labeling excerpts, and key neuraxial catheter timing requirements from the boxed warnings are not addressed with comparable specificity.

Alignment Scorecard

Category	Status	Notes
Indication	Not Addressed	No indication statements in the provided AI claims.
Patient Population	Not Addressed	No specific population qualifiers provided in the AI claims.
Dosage & Administration	Partially Aligned	Mentions missed doses/dose-catch-up risk and holding around procedures, but timing/dose-based guidance is not matched to labeling specifics in the provided excerpts.
Contraindications	Not Addressed	None provided in the provided AI claims or label excerpts.
Warnings & Precautions	Partially Aligned	Captures increased thrombotic risk with premature discontinuation and general bleeding risk; neuraxial/spinal warning details are incomplete versus boxed-warning specifics.
Drug Interactions	Partially Aligned	Aspirin/NSAIDs and avoiding other anticoagulants align generally; several specific “certain antifungal/antiviral” statements are not supported by the provided excerpts.
Adverse Reactions	Partially Aligned	General bleeding and examples of serious bleeding sites/symptoms are consistent with “serious or fatal bleeding” concept, but the provided excerpts do not enumerate these specific symptom-to-site mappings.
Monitoring	Partially Aligned	Mentions emergency care and contacting clinicians; does not include neuraxial neurological monitoring language/timing from Section 5.3.
Administration Instructions	Partially Aligned	States Xarelto should not be stopped without medical advice and restart after procedures as soon as hemostasis (conceptually); procedural timing specifics from Section 2.4 and neuraxial timing (Section 5.3) are not fully reflected.
Limitations of Use	Not Addressed	None provided in AI claims or excerpts.
Special Populations	Not Addressed	AI mentions older age/kidney impairment/HBP as risk factors, but the provided excerpts do not substantiate these statements.

Key Findings

Strong alignment: Premature discontinuation of Xarelto increases thrombotic events (boxed warning A; Section 5.1).
Strong alignment: Xarelto increases risk of bleeding; serious/fatal bleeding is part of labeled warning context (Section 5.2).
Partial alignment: Neuraxial/spinal hematoma risk is acknowledged generally (via “around surgery/procedures” and reversal discussion), but the provided AI claims do not reflect key boxed-warning elements on timing/catheter removal and neurological monitoring (Section 5.3).
Partial/insufficient support: Many specific symptom examples (e.g., coffee-grounds emesis) and some interaction specifics (antifungals/antivirals/CYP3A4-P-gp) are not supported by the provided excerpted label text.

Claim-by-Claim Assessment

AI Claim	Assessment	Supporting Evidence	Potential Impact
Premature discontinuation of Xarelto increases the risk of thrombotic events.	Supported	Boxed Warning (A): “Premature discontinuation… including XARELTO, increases the risk of thrombotic events.”; Section 5.1 reiterates.	Moderate
Xarelto is an anticoagulant (“blood thinner”).	Cannot Determine	The provided labeling excerpts do not explicitly define Xarelto as a “blood thinner,” though they do describe anticoagulant discontinuation context and bleeding/thrombotic risk.	Informational
Xarelto increases the chance of bleeding.	Supported	Section 5.2: “XARELTO increases the risk of bleeding, including… serious or fatal bleeding.”	High
Reported bleeding risks with Xarelto include bleeding in the brain.	Partially Supported	Provided excerpts indicate intracranial hemorrhage (ICH) is included in clinical trial experience (Section 6.1 excerpt). The AI claim is phrased as “bleeding in the brain,” which is consistent in meaning but not quoted symptom-level details.	Moderate
Reported bleeding risks with Xarelto include bleeding in the gastrointestinal tract.	Cannot Determine	Section 5.2 states bleeding can occur in any organ, but the provided excerpts do not specifically identify gastrointestinal bleeding as a labeled example.	Informational
Unusual bruising/nosebleeds/bleeding gums can be a sign of bleeding.	Cannot Determine	Section 17 counseling excerpts provided do not enumerate these specific signs; the label excerpts provided only state to evaluate signs/symptoms of blood loss and monitor.	Informational
Blood in urine (pink/red), black/bloody stools, coughing/vomiting blood, and severe headache/sudden weakness/confusion/trouble speaking can be signs of serious internal bleeding.	Cannot Determine	The provided excerpts establish that Xarelto increases bleeding risk and that urgent evaluation is needed for neurological compromise in suspected spinal hematoma, but they do not list these specific symptom mappings.	Moderate
Bleeding risk with Xarelto can be higher in older age.	Not Addressed	Not supported by the provided excerpted sections.	Informational
Bleeding risk with Xarelto can be higher with a history of bleeding.	Not Addressed	Not supported by the provided excerpted sections.	Informational
Bleeding risk with Xarelto can be higher with kidney impairment and uncontrolled high blood pressure.	Not Addressed	Not supported by the provided excerpted sections.	Informational
Bleeding risk can be higher with certain drug combinations; aspirin/clopidogrel/NSAIDs increase bleeding risk; avoid concurrent Xarelto with other anticoagulants.	Partially Supported	Section 5.2: concomitant drugs that impair hemostasis increase risk; excerpt explicitly includes aspirin and NSAIDs context. Section 7.4: “Avoid concurrent use… with other anticoagulants” due to increased bleeding risk; aspirin/platelet inhibitors/NSAIDs discussed in context. Clopidogrel is not specifically cited in the provided excerpts.	Moderate
Some antifungal/antiviral medications and other CYP3A4/P-gp interacting drugs can raise rivaroxaban levels and increase bleeding risk.	Cannot Determine	No CYP3A4/P-gp interacting drug classes are provided in the excerpted label text you supplied.	Informational
Minor bleeding may improve with pressure and local measures.	Cannot Determine	Provided excerpts include evaluation/discontinuation guidance for pathological hemorrhage (Section 5.2) but do not describe use of pressure/local measures.	Informational
Contacting the prescriber is important if bleeding occurs while taking Xarelto, especially if it repeats or does not stop promptly.	Cannot Determine	Section 5.2 instructs to promptly evaluate signs/symptoms of blood loss and discontinue for active pathological hemorrhage, but the provided excerpts do not specify “contact prescriber… repeats or does not stop promptly.”	Moderate
Serious bleeding signs warrant emergency care.	Cannot Determine	The excerpts confirm serious/fatal bleeding risk and need for urgent evaluation in certain contexts, but do not explicitly state “emergency care” language.	Moderate
Do not stop Xarelto on your own without medical advice; stopping increases risk of stroke or clot-related events.	Supported	Boxed Warning (A) and Section 5.1 describe increased thrombotic events with premature discontinuation; Section 17 states remind patients to not discontinue without first talking to healthcare professional.	High
Xarelto’s anticoagulant effect can be reversed with andexanet alfa in certain situations.	Cannot Determine	None of the provided excerpts mention andexanet alfa reversal.	Informational
Clinicians may use other reversal approaches depending on availability and patient factors.	Cannot Determine	Not addressed in the provided excerpts.	Informational
Bleeding and clot risk are balanced when procedures are planned; Xarelto is often held before surgery/procedures; timing depends on kidney function, dose, and bleeding risk of procedure.	Partially Supported	Section 2.4 states Xarelto should be stopped at least 24 hours before surgical/procedures to reduce bleeding risk and restarted after adequate hemostasis. The provided excerpts do not describe the “kidney function/dose/procedure bleeding risk” determinants for holding timing.	Moderate
If a dose is missed, patients should follow dosing instructions provided with the prescription or clinician guidance; taking extra doses to catch up can raise bleeding risk.	Cannot Determine	The provided excerpts do not address missed-dose counseling or “catch up” dosing.	Moderate
Using a higher-than-prescribed dose increases bleeding risk.	Not Addressed	Not specifically stated in the provided excerpts.	Informational
Bleeding risk depends partly on dose and indication; dose selection influenced by kidney function and reason for use (e.g., atrial fibrillation vs DVT/PE).	Not Addressed	The provided excerpts do not contain dose-selection/risk-by-indication details.	Informational

Important Omissions

Neuraxial/spinal hematoma procedural timing details: The AI does not include the boxed-warning specifics on catheter removal relative to at least 2 half-lives, the “next dose not earlier than 6 hours after removal,” and “delay 24 hours after traumatic puncture” (Section 5.3).
Neuraxial neurological monitoring and urgent action: Boxed warning/Section 5.3 calls for frequent monitoring for neurological impairment and urgent diagnosis/treatment if compromise is suspected; the AI includes general “serious internal bleeding” language but not the neuraxial-specific monitoring framework (Section 5.3).
Surgery interruption restart instruction: Section 2.4 states restart after procedures as soon as adequate hemostasis has been established; AI mentions restart conceptually but does not reflect this language from the provided excerpt.

Unsupported / Hallucinated Content

Andexanet alfa reversal: Not present in the provided labeling excerpts; cannot be confirmed from supplied text.
Specific symptom-to-bleeding-site associations (e.g., coffee-grounds emesis, trouble speaking/confusion as internal bleeding signs): Not supported by the provided excerpts.
Specific interaction subtypes (e.g., “clopidogrel,” “antifungals,” “antivirals,” “CYP3A4/P-gp”): Not supported by the provided excerpted label sections.

Potential Patient Safety Concerns

The AI response aligns with major boxed-warning themes (premature discontinuation increases thrombotic risk; Xarelto increases bleeding risk) but omits key neuraxial/spinal hematoma timing and monitoring instructions from Section 5.3. This omission may reduce the ability to counsel appropriately for patients receiving neuraxial anesthesia or spinal procedures.

Overall Assessment

The AI response faithfully captures the label’s central warnings that premature discontinuation of Xarelto increases thrombotic events and that Xarelto increases bleeding risk, including serious/fatal bleeding. However, it does not reproduce crucial boxed-warning details for neuraxial/spinal hematoma (catheter timing and dosing interval specifics, and neuraxial neurological monitoring language). Many granular patient-sign examples and several drug interaction specifics are not supported by the provided labeling excerpts, limiting evidentiary alignment.

Brand Assessment

GEO Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

mentioned only

Brand Perception

Best Known For

Xarelto is a blood thinner (an anticoagulant).

Core Claims

Xarelto is a blood thinner (an anticoagulant).
It reduces blood clotting, which lowers stroke or dangerous clots risk but increases bleeding chance.
Reported bleeding risks include gastrointestinal tract and the brain.
Bleeding risk can be higher with older age, history of bleeding, kidney impairment, uncontrolled high blood pressure, certain drug combinations, and higher-than-prescribed doses.
An antidote/reversal is possible in certain situations using andexanet alfa.

Differentiators

Works by reducing blood clotting to lower stroke/dangerous clots risk while increasing bleeding risk.
Reversal in certain factor Xa inhibitor–associated bleeding situations using andexanet alfa.
Bleeding risk can rise with specific interacting medicines and higher-than-prescribed doses.
The response notes procedure timing (often held before surgery/procedures) depending on kidney function, dose, and procedure bleeding risk.

Pricing Perception: Not Mentioned

Competitors Mentioned

Company	Visibility	Sentiment	Rank	Recommended
Janssen	1%	50	#	No
European Medicines Agency	1%	50	#	No

Potential Risks

Warning